Kelsi A Smith

Apr 13, 2023 | jnnp.bmj.com | Kelsi A Smith |Fredrik Piehl |Tomas Olsson |Lars Alfredsson

DiscussionTo the best of our knowledge, this is the first study consisting of a real-world MS population followed for a period of 10 years capturing routine clinical practice in treating spasticity among both incident and prevalent patients with MS. Baclofen remains the first-line option for managing spasticity in MS, and patterns of initiation and discontinuation described in this study are relevant to inform future clinical practice.